Iron Therapy :
Iron is an important element and its balance must be maintained for correct physiologic functioning. Blood loss, a serious explanation for iron deficiency, is very prevalent (e.g., females with menses and patients with chronic occult gastrointestinal (GI) blood loss) and requires proper diagnosis and management. Therapeutic management of IDA is concentrated totally on repletion of iron stores. While iron deficient individuals without
inflammation may answer oral iron therapy,
administration of IV iron is useful in many patient populations, including those with
inflammation (resulting, e.g., from renal disorder, coronary failure , or rheumatological diseases), patients who cannot tolerate oral iron, and patients who are noncompliant with oral iron therapy. Even under the simplest of circumstances, oral iron isn't well tolerated, and patients are often nonadherent for a spread of reasons, including intolerable side effects and therefore the need for multiple daily doses The frequently poor absorption of oral iron, moreover, can contribute to suboptimal patient response.
The hepcidin response in anemic patients having inflammatory conditions, like inflammatory bowel disease (IBD), inhibits GI absorption of oral iron. Moreover, hepcidin impacts iron
homeostasis in patients with concurrent
inflammation (e.g., repressed recycling of iron from the RES and sequestration in bone marrow); this might limit both oral and IV iron supplementation and should serve to elucidate why such patients remain iron deficient despite multiple courses of therapy. Cancer-related
anemia (CRA) has multiple etiologies, including chemotherapy-induced myelosuppression, blood loss, functional iron deficiency,
erythropoietin deficiency thanks to renal disease, and marrow involvement with tumor, among others. the foremost common treatment options for CRA include iron therapy, erythropoietic-stimulating agents (ESAs), and red cell transfusion.
High Impact List of Articles
Relevant Topics in Medical